<DOC>
	<DOCNO>NCT02963103</DOCNO>
	<brief_summary>The objective study observe evaluate change renal function follow conversion cyclosporine-based immunosuppressive regimen tacrolimus-based one .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy Tacrolimus Based Immunosuppressive Regimen Stable Kidney Transplant Recipients Converted From Cyclosporine Based Immunosuppressive Regimen</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patients receive kidney transplant least 12 month enrollment . Patients whose dosage previous immunosuppressant change remain least 4 week enrollment , blood trough level cyclosporine 100 200 ng/mL . Patients side effect ( hypertension , hyperlipidemia , gingival hyperplasia hypertrichosis/hirsutism ) use cyclosporine . Serum creatinine &lt; 2.3 mg/dl enrollment Female patient childbearing potential must negative serum pregnancy test prior enrollment , agree use effective contraception trial . Patients consider clinically stable Patients previously receive organ transplant kidney . Patients acute transplant rejection within 12 week , acute transplant rejection require antilymphocyte therapy within 24 week prior enrollment . Patients newly diagnose malignant tumor organ transplant , patient treat completely basal squamous cell carcinoma skin except . Patients underlying disease focal segmental glomerulosclerosis ( FSGS ) type II membranoproliferative glomerulonephritis ( Type II MPGN ) . Proteinuria &gt; 2 g/24 hr . Patients `` Creeping creatinine '' ( 20 % increase creatinine six month enrollment ) . Patients whose Alanine Aminotransferase ( ALT ) and/or Aspartate Aminotransferase ( AST ) twice high normal range center . Patients liver cirrhosis . Patients pregnant breastfeeding . Patients HIVpositive . Patients know allergy PrografÂ® ingredient , steroid adjuvant . Patients unstable medical condition may affect evaluation study 's objective . Patients receive prohibit concomitant medication receive medication within 28 day enrollment . Patients currently participate another clinical trial receive investigational drug another trial within 28 day enrollment . Patients risk drug abuse mental disorder communicate difficulty .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Kidney transplantation</keyword>
</DOC>